drugset / Trial / NCT00519831
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
Phase 2
Terminated
18 enrolled
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as vinflunine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and help kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Giving vinflunine together with cetuximab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving vinflunine together with cetuximab works as second-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer.
Timeline
- Start
- 2007-08
- Primary completion
- 2008-02
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Vinflunine | Small molecule | 320 mg/m2 | Intravenous |